JP5675360B2 - Ｐｉ３ｋ阻害剤としてのチエノピリミジエン誘導体 - Google Patents

Ｐｉ３ｋ阻害剤としてのチエノピリミジエン誘導体 Download PDF

Info

Publication number
JP5675360B2
JP5675360B2 JP2010530548A JP2010530548A JP5675360B2 JP 5675360 B2 JP5675360 B2 JP 5675360B2 JP 2010530548 A JP2010530548 A JP 2010530548A JP 2010530548 A JP2010530548 A JP 2010530548A JP 5675360 B2 JP5675360 B2 JP 5675360B2
Authority
JP
Japan
Prior art keywords
thieno
morpholin
ylmethyl
indol
diaza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010530548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500774A (ja
JP2011500774A5 (https=
Inventor
ハンコックス，ティモシー・コリン
ペグ，ニール・アンソニー
ナディン，アラン・ジョン
プライス，スティーヴン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2011500774A publication Critical patent/JP2011500774A/ja
Publication of JP2011500774A5 publication Critical patent/JP2011500774A5/ja
Application granted granted Critical
Publication of JP5675360B2 publication Critical patent/JP5675360B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2010530548A 2007-10-26 2008-10-27 Ｐｉ３ｋ阻害剤としてのチエノピリミジエン誘導体 Expired - Fee Related JP5675360B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0721095.8A GB0721095D0 (en) 2007-10-26 2007-10-26 Pharmaceutical compounds
GB0721095.8 2007-10-26
PCT/GB2008/003621 WO2009053715A1 (en) 2007-10-26 2008-10-27 Thienopyrimidiene derivatives as pi3k inhibitors

Publications (3)

Publication Number Publication Date
JP2011500774A JP2011500774A (ja) 2011-01-06
JP2011500774A5 JP2011500774A5 (https=) 2011-12-15
JP5675360B2 true JP5675360B2 (ja) 2015-02-25

Family

ID=38830047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530548A Expired - Fee Related JP5675360B2 (ja) 2007-10-26 2008-10-27 Ｐｉ３ｋ阻害剤としてのチエノピリミジエン誘導体

Country Status (8)

Country Link
US (1) US8293735B2 (https=)
EP (1) EP2205610B1 (https=)
JP (1) JP5675360B2 (https=)
CN (1) CN101868464B (https=)
CA (1) CA2701276A1 (https=)
ES (1) ES2442501T3 (https=)
GB (1) GB0721095D0 (https=)
WO (1) WO2009053715A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
CA2772371A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CN102459272B (zh) 2009-05-27 2014-08-06 健泰科生物技术公司 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
EP3399026B1 (en) 2010-06-14 2024-06-26 The Scripps Research Institute Reprogramming of cells to a new fate
CN103313989B (zh) 2010-12-16 2016-05-04 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
ES2464598T3 (es) 2011-07-22 2014-06-03 Université Joseph Fourier Nuevos derivados bis-indólicos, procedimiento para su preparación, y sus utilizaciones como fármaco
JP6301316B2 (ja) 2012-05-23 2018-03-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法
MX361157B (es) * 2012-08-30 2018-11-28 Hoffmann La Roche Compuestos inhibidores de pi3k de dioxino- y oxazin-[2,3-d]pirimid ina y métodos de uso.
GB201402431D0 (en) * 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
US10591000B2 (en) * 2016-05-24 2020-03-17 Means Industries, Inc. One-way clutch assembly and coupling member for therein wherein locking member dynamics with respect to strut laydown speed are enhanced
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AU2019416623B2 (en) * 2018-12-27 2022-12-08 Holosmedic Novel compound and pharmaceutical composition comprising same for enhancing anticancer activity
KR102338609B1 (ko) * 2019-05-20 2021-12-14 보령제약 주식회사 피리도-피리미딘 화합물 및 이를 유효성분으로 포함하는 pi3k 관련 질환의 예방 또는 치료용 약학적 조성물
WO2020234103A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Identification and use of kras inhibitors
WO2020243459A1 (en) * 2019-05-31 2020-12-03 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors
WO2021086038A1 (ko) * 2019-10-31 2021-05-06 홀로스메딕 주식회사 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물
CN112920199B (zh) * 2020-06-02 2023-02-03 四川大学 一种哌嗪酮取代物或其衍生物及其制备方法和应用、药物组合物
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
CH592668A5 (https=) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
DE69943144D1 (de) * 1998-03-31 2011-03-03 Kyowa Hakko Kirin Co Ltd Stickstoffenthaltende heterocyclische verbindungen
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US20020156601A1 (en) * 2001-04-19 2002-10-24 Tu Kevin Hsiaohsu Event monitoring and detection system
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
RU2008141356A (ru) * 2006-04-26 2010-06-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные пиримидина в качестве ингибиторов фосфатидилинозитол-3-киназы (pi3k)
TWI498332B (zh) * 2006-04-26 2015-09-01 Hoffmann La Roche 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
MX2008013578A (es) * 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
CN101511840A (zh) * 2006-04-26 2009-08-19 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物及其使用方法
GB0608820D0 (en) * 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
ES2571028T3 (es) * 2006-12-07 2016-05-23 Genentech Inc Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
WO2008070740A1 (en) * 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
AU2008298948B2 (en) * 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042607A1 (en) * 2007-09-24 2009-04-02 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
US8354528B2 (en) * 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
CN101835779B (zh) 2007-10-26 2014-01-29 霍夫曼-拉罗奇有限公司 作为pi3激酶抑制剂的嘌呤衍生物
JP2011521968A (ja) * 2008-05-30 2011-07-28 ジェネンテック， インコーポレイテッド プリンｐｉ３ｋ阻害剤化合物および使用方法
CN102459272B (zh) * 2009-05-27 2014-08-06 健泰科生物技术公司 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法
CA2772371A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use

Also Published As

Publication number Publication date
JP2011500774A (ja) 2011-01-06
ES2442501T3 (es) 2014-02-11
US20110021496A1 (en) 2011-01-27
US8293735B2 (en) 2012-10-23
CN101868464B (zh) 2013-11-13
EP2205610B1 (en) 2013-11-20
CA2701276A1 (en) 2009-04-30
WO2009053715A1 (en) 2009-04-30
EP2205610A1 (en) 2010-07-14
WO2009053715A8 (en) 2010-06-03
CN101868464A (zh) 2010-10-20
GB0721095D0 (en) 2007-12-05

Similar Documents

Publication Publication Date Title
JP5675360B2 (ja) Ｐｉ３ｋ阻害剤としてのチエノピリミジエン誘導体
JP5539190B2 (ja) チアゾロピリミジン類及びホスファチジルイノシトール−３キナーゼのインヒビターとしてのそれらの使用
JP5781066B2 (ja) ｐ１１０δに対して選択的な二環式ピリミジンＰＩ３Ｋ阻害剤化合物及び使用方法
CN111065626B (zh) 用于治疗亨廷顿氏舞蹈病的化合物
EP2215090B1 (en) Purine derivatives useful as pi3 kinase inhibitors
KR101548439B1 (ko) 트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법
KR101787680B1 (ko) 키나아제 억제제 및 이의 용도
WO2008152394A1 (en) Pharmaceutical compounds
BR112021001292A2 (pt) compostos heterobicíclicos para inibir a atividade de shp2
CN117957226A (zh) 作为sos1抑制剂的杂环化合物及其用途
AU2014207691A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
CA2878054A1 (en) Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
TW202302604A (zh) 新穎噻唑并嘧啶酮衍生物
CN106946909A (zh) 抗肺结核病的硝基咪唑衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111025

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140909

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141224

R150 Certificate of patent or registration of utility model

Ref document number: 5675360

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees